Sanofi Reports Positive Results From Phase 3 Dupixent Study

(RTTNews) - Sanofi reported that the detailed results from a Phase 3 trial showed Dupixent (dupilumab) monotherapy demonstrated a significant improvement in signs and symptoms of atopic dermatitis and certain quality of life measures in adolescent patients (12-17 years) with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable. The company said the results from the trial in adolescents form the basis of regulatory submissions for patients ages 12 to 17.

Amy Paller, Director of the Northwestern University Skin Disease Research Center and principal investigator of the trial, said: "The results we are presenting today show the potential for Dupixent in adolescents to not only help clear the skin and reduce itching, but also improve certain aspects of quality of life in adolescents who may be dealing with these unbearable symptoms."